search for




 

A Case of Severe Pneumocystis Pneumonia in a Thyroid Cancer Patient Receiving Lenvatinib
Int J Thyroidol 2019;12(2):127-131
Published online November 30, 2019;  https://doi.org/10.11106/ijt.2019.12.2.127
© 2019 Korean Thyroid Association.

Mei Hua Jin, Won Gu Kim, Tae Yong Kim, Won Bae Kim, Young Kee Shong and Min Ji Jeon

Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
Correspondence to: Min Ji Jeon, MD, PhD, Division of Endocrinology and Metabolism, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul 05505, Korea
Tel: 82-2-3010-1317, Fax: 82-2-3010-6962, E-mail: mj080332@gmail.com
Received October 12, 2019; Revised November 19, 2019; Accepted November 20, 2019.
This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
Lenvatinib is a multitargeted tyrosine kinase inhibitor approved for use in patients with iodine-131–refractory thyroid cancer. The common adverse events of lenvatinib include hypertension, proteinuria, fatigue, and diarrhea. To date, no report on Pneumocystis pneumonia (PCP) in patients receiving lenvatinib has been published. Here, we present a case of severe PCP that led to the death of a 79-year-old woman who was diagnosed with poorly differentiated thyroid cancer and received lenvatinib. The development of PCP should be considered when patients taking lenvatinib show clinical symptoms of pneumonia, and regular chest X-ray follow-up is needed for patients receiving lenvatinib.
Keywords : Lenvatinib, Pneumocystis pneumonia, Interstitial pneumonia, Thyroid cancer


November 2019, 12 (2)